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Birgitte V. Offersen, MD, PHD,h Marianne Jarfelt, MD, PHD,i Geeta Gulati, MD, PHDj,kC ardio-oncology is a relatively new, albeitquickly expanding field. The efficacy ofmodern cancer therapy has increased the
number of long-term cancer survivors. However, the
long-term survival for cancer patients may in some
cases be limited by cardiovascular toxicities second-
ary to necessary cancer treatment. Cardiovascular
mortality has been shown to surpass cancer related
mortality in breast (1), hematologic (2), and childhood
cancers (3). Cardiologists and oncologists have
different approaches to cardio-oncology due to theirISSN 2666-0873
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instructions page.different clinical roles. A collaborative approach be-
tween the 2 fields is necessary to achieve the best
possible cancer outcomes with minimal injury to the
cardiovascular system.
Individually the Nordic countries have small pop-
ulations ranging between 350,000 and 10 million
(Table 1), and together they comprise a population of
more than 27 million people (4). The backbone of the
Nordic countries’ general health care is a public,
taxation-based system with equal access for all citi-
zens. Although management, steering systems, and
user fees differ between the countries, they all pro-
vide high-quality care. Educational systems are also
similar with well-established medical universities
providing a high-standard medical education and
front-line research.
There is a history of collaboration between clinical
and research networks with examples from shared
health statistics, including the Nordic Medico-
Statistical Committee (5). The Nordic Society of Pe-
diatric Hematology and Oncology (6) also stands out
for its comprehensive educational program and
broadly supported clinical management guidelines,
as it has inspired long-term follow-up national
guidelines for childhood cancer survivors including
cardiovascular surveillance. Based on these experi-
ences and bearing in mind that knowledge grows
when shared, the Nordic Cardio-Oncology Society
(NCOS) was formed.
The overall goal for the NCOS is improved cardio-
vascular outcomes for patients treated for cancer. By
creating a Nordic arena of collaboration, we hope to
facilitate the implementation of practice-changing
evidence for the prevention or treatment of car-
diotoxicity more quickly. The first board meeting was
held in the morning of November 8, 2019, at Garder-
moen, Oslo, Norway, right before the first NCOShttps://doi.org/10.1016/j.jaccao.2020.04.004
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334Summit, establishing the aims and tasks of the NCOS.
The board consists of a total of 11 people, 1 from the
field of cardiology and 1 from the field of oncology
from Denmark, Finland, Iceland, Norway, and Swe-
den and going forward, the past president will be
included. The board agreed that the NCOS would
apply for affiliation with the International Cardio-
Oncology Society (ICOS). The goals of NCOS will be
published on the ICOS webpage.
In the afternoon, while the first snow fell, 58 par-
ticipants from Denmark, Finland, Iceland, Norway,
and Sweden gathered to learn about cardio-oncology
at the first NCOS Summit. About half of the partici-
pants had a cardiology perspective and the other half
had an oncology perspective. The meeting was
opened by a talk titled “What is Cardio-Oncology”
from one of the keynote speakers, Dr. Alexander Lyon
from the Royal Brompton Hospital, London, England.
Dr. Lyon is the president of the British Cardio-
Oncology Society and a member of the European So-
ciety of Cardiology Cardio-Oncology Council Board.
He gave a general perspective of the field of cardio-
oncology and set the stage for the rest of the day.
He started his talk by saying that “cancer and car-
diovascular disease are two medical worlds
colliding.” Hopefully, through our newly formed
collaboration, we can create an aftermath of this
collision that is beneficial for our patients. Dr. Lyon
continued by providing an overview of the most
important cardiotoxic cancer treatment regimens as
anthracyclines, trastuzumab, and radiation therapy.
Further, he presented data on immunotherapy
showing that it has radically improved cancer sur-
vival; however, severe myocarditis can be a fatal
complication. Different cancer treatments and their
effects on the cardiovascular system were explored in
detail by other Nordic speakers during the Summit.
The second keynote speaker was Dr. Peter van der
Meer from the University Medical Center Groningen
in the Netherlands. Dr. van der Meer is also a board
member of the European Society of Cardiology Car-
dio-Oncology Council Board. He gave a talk on “What
do the Experts say — Position Paper in Cardio-Oncology” and provided an overview of the evidence
for cardio-protective treatment in cardio-oncology.
The patients are our central focus. To highlight the
importance of balanced information to the patient
about potential cardiac side effects by cancer treat-
ment without discouraging them from accepting
cancer treatment, a patient was invited to share her
story. She had previously been treated for breast
cancer with anthracyclines, and shared her experi-
ence in participating in a randomized, placebo-
controlled clinical trial. The patient emphasized the
importance of balanced information both from the
oncologist and cardiologist. She also talked about the
patients perspective of participating in a clinical trial,
noting that participation can be reassuring as it gives
a feeling of being taken better care of.
The session on “Research and Perspective for
Nordic Collaboration” was opened by Professor
Torbjørn Omland from Akershus University Hospital,
Norway. He is the Principal Investigator of and initi-
ated both the PRADA (Prevention of Cardiac
Dysfunction During Adjuvant Breast Cancer Therapy)
(7) and PRADA II trials. He gave an overview of ran-
domized controlled trials on cardioprotective treat-
ment during anthracycline and/or trastuzumab
treatment. He, together with speakers from Denmark,
Finland, and Sweden then gave an overview of
cardio-oncology trials in their respective countries
and the possibilities for collaboration.
Speakers from the different Nordic countries pre-
sented some of the local, regional, and national ini-
tiatives in cardio-oncology that have evolved during
the past years. Multidisciplinary aspects and other
collaborative activities were depicted and all spoke to
the common theme of the importance of strength-
ening the presently fragmented cardio-oncology
collaborative networks and the need of a common
arena for sharing questions and knowledge.
All the Nordic countries have cardio-oncology
units at some of their hospitals, but commonly these
are local initiatives directed by 1 or 2 enthusiastic
cardio-oncologists. However, driven by the demand
from professionals and patients for evidence and in-
formation, more structured cardio-oncology activities
are emerging. On a national level, Denmark has
established an operative “onco-cardiology” network
group within the Danish Comprehensive Cancer
Center. In Sweden, a cardio-oncology initiative has
been started within the heart failure working group of
the Swedish Cardiology Association. Furthermore,
rehabilitation after cancer is managed through a
cooperation of the Swedish Regional Cancer Centers
where the National Program for Long Term Follow up
after Childhood Cancer also serves as a good example
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335of comprehensive risk assessment based screening
program for all cancers, stratified by treatment. By
establishing NCOS and holding summits where we
can share our experiences, we can learn from each
other and establish more robust cardio-oncology
clinics at our hospitals.
If smaller countries can share clinical experi-
ences, and collaborate in research projects with
neighboring countries, this will hopefully result in
platforms for larger randomized studies with higher
clinical impact. In this way the Nordic countries are
unique, as they have similar health systems and a
tradition of collaboration across borders supported
by similar regulatory systems. The main challenge is
to establish relevant platforms for clinical and sci-
entific encounters. We believe this summit was the
beautiful start of such networking. We are in an
establishment phase, perhaps the most difficult
phase. Inspired by the experiences of China (8) and
Israel (9), we are prepared for a long-standing
development phase beginning with the formal
registration of the organization. Concomitantly, the
NCOS is working on a financial strategy for securinga website where Nordic cardio-oncology clinics and
research projects in cardio-oncology can register to
find collaborators and others interested in the same
questions.
The NCOS is working towards the goal of being the
arena for Nordic educational and research
networking, and aims to be acknowledged by the
national cardiology and oncology societies. The
NCOS’ aim is to support the present cardio-oncology
care providers, and we believe that supporting
educational and research networks today create to-
morrow’s scientists and clinicians. The NCOS will
encourage cardio-oncologists in the Nordic countries
to take the ICOS Certification Exam.
We look forward to evaluating our progress at our
next Nordic Cardio-Oncology Summit planned to be
held in Finland in 2021.
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